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Respiratory syncytial virus subunit vaccines based on 
the viral envelope glycoproteins intended for pregnant 
women and the elderly
 
Max Beugeling, Jildou De Zee, Herman J. Woerdenbag, 








Introduction: Respiratory syncytial virus (RSV) causes high morbidity and mortality 
rates among infants, young children, and the elderly worldwide. Unfortunately, a safe 
and effective vaccine is still unavailable. In 1966, a formalin-inactivated RSV vaccine 
failed and resulted in the death of two young children. This failure shifted research 
toward the development of subunit-based vaccines for pregnant women (to passively 
vaccinate infants) and the elderly. Among these subunit-based vaccines, the viral 
envelope glycoproteins show great potential as antigens. Areas	covered:	In this review, 
progress in the development of safe and effective subunit RSV vaccines based on the 
viral envelope glycoproteins and intended for pregnant women and the elderly, are 
reviewed and discussed. Studies published in the period 2012-2018 were included. 
Expert	opinion: Researchers are close to bringing safe and effective subunit-based RSV 
vaccines to the market using the viral envelope glycoproteins as antigens. However, it 
remains a major challenge to elicit protective immunity, with a formulation that has 
sufficient (storage) stability. These issues may be overcome by using the RSV fusion 
protein in its pre-fusion conformation, and by formulating this protein as a dry powder. 
It may further be convenient to administer this powder via the pulmonary route.
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Human respiratory syncytial virus (RSV) is the most important cause of severe lower 
respiratory tract infections among infants and young children worldwide [1–4]. It 
has been estimated that, in 2015, globally 33.1 million children under 5 years of age 
suffered from RSV-associated acute lower respiratory infection (RSV-ALRI). Of these 
children, 3.2 million required hospitalization. In that same year, approximately 118,200 
children deceased from RSV-ALRI [5]. RSV is also an important cause of severe morbidity 
and mortality among the elderly (≥ 65 years) [6].
 The virus is transmitted via aerosols and through contact with contaminated 
surfaces [7]. After an initial RSV infection there is usually no long-lasting immunological 
memory against RSV. As a result, reinfections occur frequently [8]. Hall et al. [9] 
demonstrated this by challenging adults with RSV after a natural infection. Almost 
50% of them were reinfected within 2 months. In the study period of 26 months, 
73% were infected at least twice, and 47% were even infected three times or more. 
However, two subsequent infections within a short period of time tended to improve 
the immunological memory. Higher serum antibody levels before RSV challenge 
correlated with protection from infection, but the rate of reinfection was still 25% 
among subjects with the highest antibody titers.
 Despite the significant global health burden and over 50 years of research, no 
vaccine against RSV is available on the market yet. Currently, palivizumab is the only 
approved therapeutic agent against RSV infection [10]. This monoclonal antibody binds 
to the fusion (F) protein of the virus [11,12]. Palivizumab is only used prophylactically 
with infants who are at high risk for hospitalization due to RSV infection and it needs 
to be administered monthly for a longer period [13]. The high costs of multiple dosing 
with palivizumab restricts its use, especially in low- and middle-income countries [12]. 
Moreover, repeated injections are a burden for the patient. 
 Ribavirin, a nucleoside analog, is also used for the treatment of RSV infection in 
high-risk patients [14]. Usually, it is administered pulmonary in an aerosolized form. 
Treatment with ribavirin has limitations: it is very costly, difficult to administer, and 
has limited clinical efficacy [12,15].
 In view of the current drawbacks in RSV prophylaxis and therapy, the 
development of a safe and effective RSV vaccine is urgently needed. In a trial in 1966, 
formalin-inactivated virus (FI-RSV) was used as a vaccine. This vaccine candidate was 
investigated in infants and young children and yielded moderate serum antibody 
levels, but appeared to be unable to protect against RSV infection [16,17]. By contrast, 
vaccinated infants even developed more serious lower respiratory tract disease upon 
natural RSV infection than did infants who had not received the FI-RSV vaccine. This 
phenomenon is known as vaccine-enhanced respiratory disease [18]. Two of the thirty-
one vaccinated children died during the trial [17]. The failure of the FI-RSV vaccine 
hampered research toward new RSV vaccines for many years after that study. 
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 In recent years, however, extensive research was done on the development of 
an RSV vaccine and researchers are getting closer to bringing a safe and effective 
vaccine to the market. In December 2015, 60 different RSV vaccine candidates were in 
preclinical or clinical development [12]. Many different approaches have been followed 
in the development of an effective RSV vaccine (e.g. live-attenuated, whole inactivated, 
subunit-based vaccines), as different target groups for RSV vaccination require 
different vaccine formulations [19–21]. The different target groups for RSV vaccination 
are: infants (≤ 6 months of age), young children (6-24 months of age), pregnant 
women (to passively vaccinate neonates), and the elderly (≥ 65 years of age) [19–21]. 
The target group with the highest priority is infants [20]. However, since the failure 
of the FI-RSV vaccine, vaccinating this specific target group encounters resistance 
and remains elusive. On the other hand, a growing interest is seen for vaccination of 
pregnant women. The goal of vaccinating this target group is to induce high titers 
of neutralizing antibodies which are passively transferred to the fetus and thus may 
protect infants during the crucial first months of life [19,20,22]. According to Anderson 
et al. [20], subunit-based vaccines are considered for this purpose, as live RSV vaccines 
have not been sufficiently immunogenic in adults.
 For the same reason, subunit-based vaccines are also considered for another 
important target group, being the elderly [20]. A major challenge of this target group 
is immunosenescence, which may result in an unbalanced immune response [19]. 
Therefore, it is likely that a subunit-based vaccine for the elderly will have to be co-
formulated with adjuvants to recall pre-existing immunity and to elicit a balanced 
immune response [21]. For both target groups, pregnant women and the elderly, 
vaccine-enhanced respiratory disease is considered not to be a concern, since these 
target groups have been infected with a live virus multiple times [20,23]. In conclusion, 
subunit-based RSV vaccines show great promise for different target groups.
 Several antigens can potentially be used for the development of subunit-based 
RSV vaccines. However, from recent literature it is clear that the F protein is considered 
as the most promising antigen. This is also supported by the fact that virus-neutralizing 
(VN) antibodies are targeted at this glycoprotein upon RSV infection [24].
 This review focuses on the viral envelope glycoproteins, and in particular the F 
protein (in both the pre-fusion (pre-F) and the post-fusion (post-F) conformation), as 
antigens. The structure of RSV and the viral envelope glycoproteins are first discussed, 
after which recent advances in the development of subunit-based RSV vaccines, using 
the viral envelope glycoproteins as antigens, are reviewed. For the latter part, only 
studies published in the period 2012-2018 were included. The review was conducted 
using PubMed and the following search terms were used: respiratory syncytial virus, 
vaccine, attachment protein, fusion protein, virosomes, structure, hospitalization, and 
treatment.
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RSV is an enveloped, negative-sense, single-stranded RNA virus, which belongs to the 
genus Orthopneumovirus of the family Pneumoviridae [25,26]. This family also includes 
human metapneumovirus, which after RSV represents the second most common cause 
of lower respiratory tract infections among young children [27]. Two different subtypes 
of RSV can be distinguished, namely RSV A and RSV B [28]. The structure of the virus is 
shown in Fig. 1 [29]. The virus consists of a lipid envelope containing a nucleocapsid, 
and is pleomorphic with different sizes of spherical particles and filamentous particles 
[30]. The RSV genome contains approximately 15,200 nucleotides, encoding 11 
different proteins [31]. The transmembrane surface glycoproteins protrude from the 
outside of the lipid bilayer and are 11-20 nm in size [29]. The RSV genome, proteins, 
and their functions are shown in Fig. 2 [29].
NS1 and NS2 are non-structural proteins, which are not packaged inside RSV 
virions, but only detected in RSV-infected cells [32]. They mainly inhibit the production 
of interferon (IFN), specifically IFN-α and IFN-β, by the host cell [33]. The nucleocapsid 
(N) protein offers protection for the viral RNA. N and phosphoprotein (P) are essential for 
transcriptional activity [29]. The matrix (M) protein is important for virus assembly, as 
it connects the nucleocapsid with the envelope proteins [29,34]. The M2 gene encodes 
two proteins, M2-1 and M2-2. M2-1 functions as an elongation factor in transcription 
and M2-2 is involved in regulation of viral RNA transcription and replication [35,36]. 
The long gene L encodes the RNA polymerase of the virus [27,29], which replicates the 
viral RNA and is also involved in polyadenylation, capping, and methylation [29,37].
Three different proteins are present on the outer surface of the virus membrane:
Fig.	1.	Structure of RSV [29]. The nucleocapsid is a symmetrical helix and is surrounded by a lipid 
envelope. The surface proteins F, G, and SH protrude from the outside of the lipid bilayer.
Subunit-based RSV vaccine candidates | Chapter 4
547040-L-sub01-bw-Beugeling
Processed on: 27-8-2020 PDF page: 60
60
Fig.	2.	The RSV genome, proteins, and their functions [29]. The genome contains 15,200 nucleotides, 
encoding 11 different proteins.
the F protein, the G protein, and the small hydrophobic (SH) protein [24]. The F and G 
proteins are the viral envelope glycoproteins, which will be discussed in more detail in 
the next section. The SH protein is a small protein that is found in infected cells and 
on the membrane of the virus [24]. The SH protein forms a pentameric ion channel 
complex. Its biological function is still unknown [38].
THE	VIRAL	ENVELOPE	GLYCOPROTEINS
 
This section is devoted to the viral envelope glycoproteins. The viral envelope 
glycoproteins, the F protein and the G protein, are involved in virus entry into the target 
cell. G is the receptor-binding protein, while F has membrane fusion activity. Both 
proteins have been shown to elicit VN antibodies [24]. Clearly, antibodies directed to G 
interfere with binding of RSV virions to cellular receptors, while antibodies directed to 
F inhibit viral membrane fusion. Therefore, these glycoproteins are promising antigens 
in the development of a subunit vaccine against RSV [39].
The	F	protein
 
As already mentioned above, the RSV F protein is crucial for virus cell entry, mediating 
fusion of the viral envelope with the host cell plasma membrane [24]. Through this 
fusion event, the viral genome is deposited into the cytosol of the host cell. The RSV F 
protein belongs to the so-called type I viral membrane fusion proteins [24,40]. When the 
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F protein is expressed at the surface of infected cells, it can also induce the formation 
of syncytia by mediating fusion between neighboring cells [24,40]. The F gene encodes 
an inactive precursor protein, F
0
. A trimer is assembled consisting of three identical F
0
 
monomers [24]. The F
0 
precursor protein is activated by proteolytic cleavage at two 






 (23 kDa) subunit 




 subunits are 
covalently linked by two disulfide bonds [24]. The first cleavage occurs in the producer 
cells and generates the F
2
 and the F
1
 subunits [43]. There are indications that the second 
proteolytic cleavage, resulting in the release of p27, occurs after macropinocytosis 
[43]. It is known that nucleolin on the cell surface can mediate macropinocytosis [44]. 
Interestingly, Tayyari et al. [45] identified nucleolin as cellular receptor for the F protein, 
suggesting the involvement of nucleolin in macropinocytosis of RSV. The release of 
p27 generates a hydrophobic N terminus of F
1
, which is known as the fusion peptide 
of the mature pre-F form of the protein [41,43]. It is the mature pre-F conformation of 
the F protein that has the capacity to induce membrane fusion by partially refolding 
and inserting its hydrophobic fusion peptide into the target membrane [24,40,41]. 
The fusion event is then further facilitated by a conformational change from pre-F to 
post-F [41]. The trigger for the fusion event is still unknown [24,41]. Fig. 3 shows the 
structures of pre-F and post-F [41].
The F proteins of the two subtypes, RSV A and RSV B, are at least 90% identical in 
amino acid sequence [24]. As described above, the F protein is located on the surface of 
the virus and is essential for virus cell entry. This makes the F protein an ideal antigen 
for the development of subunit-based RSV vaccines [24]. However, both the pre-F 
and the post-F protein have their shortcomings as antigen for an RSV vaccine. Clearly, 
effective VN antibodies need to interact with the pre-F conformation of the F protein, 
thus blocking fusion between the viral envelope and the host cell membrane [46]. 
Accordingly, it would appear that pre-F is the preferred conformation of F in a vaccine 
candidate. However, pre-F is a metastable protein, which readily flips into the stable 
post-F conformation, also in absence of membrane interaction of the protein [46,47]. 
Post-F may be used as an antigen because it shares antigenic epitopes with pre-F (sites 
II and IV, see Fig. 3) [41,47,48]. Therefore, antibodies elicited against post-F may still be 
able to neutralize viral membrane fusion activity mediated by pre-F. However, post-F 
lacks several epitopes of pre-F, including the well characterized antigenic site Ø (see 
Fig. 3) [24,47,49], which tertiary structure changes during the transition from pre-F to 
post-F [41]. Other pre-F-specific epitopes, such as the antigenic site VIII (comprising 
parts of sites II, V, and Ø) [41,50] and a quaternary pre-F-specific epitope (positioned 
halfway between the membrane-proximal region and the apex of the pre-F trimer) 
[41,51] have recently been characterized. Therefore, post-F, although stable and thus 
more practical to work with than pre-F, would appear to be the less favorable antigen 
for the induction of fusion-inhibitory activity, and thus VN antibodies.
Subunit-based RSV vaccine candidates | Chapter 4
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The G protein is glycosylated, which is important for attachment to the target cell [29]. 
The main receptor for the G protein appears to be the CX3CR1 chemokine receptor 
[24,52], although other cellular proteins have been implicated in receptor binding of 
RSV as well [24]. RSV G also binds to heparin sulfate, found on the surface of most 
cells [24]. The main difference between RSV A and RSV B is the amino acid sequence 
of the G proteins [28,29]. VN antibodies directed against the G proteins of both RSV 
subtypes might be needed to provide sufficient protection against RSV [28]. However, 
it has been shown that the addition of the G protein to F protein-based vaccines may 
enhance VN antibody titers [53–55].
Fig.	3. Structures of pre-F (upper) and post-F (lower) [41]. The left panels show the structures of pre-F 
and post-F with one monomer depicted as a ribbon. The right panels show the structures of pre-F 
and post-F with three monomers. The antigenic sites are indicated with color (red: site Ø, blue: site 
I, yellow: site II, green: site III, magenta: site IV, and orange: site V). 
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RSV	 SUBUNIT	 VACCINE	 CANDIDATES	 BASED	 ON	 THE	 VIRAL	 ENVELOPE	
GLYCOPROTEINS
 
As of late, the scientific community is getting closer to the development of a safe 
and effective subunit-based RSV vaccine using the viral envelope glycoproteins as 
antigens. A concern in the development of an RSV vaccine, is that RSV infections, and 
thus potentially also vaccination, do not induce (long-lasting) protective immunity. In 
addition, since subunit-based vaccines are composed of non-replicating component(s) 
of the virus, they are often poorly immunogenic [56,57]. Another concern is the quality 
of the immune response. For optimal protection, a balanced Th1/Th2 response is 
desired for the induction of immunological memory, cellular immunity, and potent 
VN antibodies [58]. To meet these requirements, subunit-based vaccines may require 
adjuvants and/or multiple administrations to boost the immune response [56–58]. 
Other ways to boost the immune response and to regulate the Th1/Th2 response 
include the formulation of virus-like particles (VLPs), nanoparticles, and virosomes. 
The focus of this review is on subunit-based RSV vaccines using the viral envelope 
glycoproteins, in particular the F protein, as antigens. These candidates include vaccines 
based on soluble viral envelope glycoprotein, VLPs, nanoparticles, and virosomes.
Soluble	viral	envelope	glycoprotein	vaccines
 
Recently, protein engineering has gained considerable interest as a tool to develop 
effective subunit-based vaccines [59]. By using this technique, tailor-made subunit-
based vaccines may be produced and the stability and/or immunogenicity of the 
vaccine may be improved. Another way to increase the immunogenicity and control 
the Th1/Th2 response of subunit-based vaccines is the use of adjuvants. However, 
only a few adjuvants are licensed for human use [56]. Therefore, novel adjuvants have 
recently been developed and evaluated in combination with subunit-based vaccines. 
This section reviews strategies applied to develop safe and efficient soluble viral 
envelope glycoprotein vaccines. Vaccine candidates tested in preclinical studies are 
first discussed, followed by an overview of candidates tested in clinical studies. Table 1 
gives an overview of the in vivo studies discussed in this review that used soluble viral 
envelope glycoprotein, in particular the F protein, as vaccine candidates.
Vaccine candidates in preclinical development
    
McLellan et al. [49] designed a soluble pre-F antigen called DS-Cav1. It was attempted to 
stabilize this antigen in the trimeric pre-F conformation by introducing disulfide bonds 
(DS), filling hydrophobic cavities with hydrophobic substitutions (Cav1), and retaining 
Subunit-based RSV vaccine candidates | Chapter 4
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the C-terminal trimerization domain. A two-dose intramuscular immunization of 
CB6F1/J mice and rhesus macaques with DS-Cav1 adjuvanted with poly I:C (synthetic 
double-stranded RNA) resulted in high titers of VN antibodies, directed against the 
antigenic site Ø of the pre-F protein. These VN antibodies are also known as D25-
competing antibodies, as D25 is a monoclonal antibody binding to antigenic site Ø. 
These high titers make DS-Cav1 a promising candidate for an effective RSV vaccine. 
However, it has been shown that DS-Cav1 (in an aqueous solution) is not stable during 
prolonged storage (102 days) at 4 °C [60]. The conformation of DS-Cav1 changed to one 
that was distinct from the pre-F and the post-F conformation of the protein [60]. In the 
changed conformation, the specific antigenic site Ø was lost, which is an important 
target for VN antibodies as argued above. Therefore, an improved version of DS-Cav1 
was designed, which resulted in the second generation DS-Cav1, named DS2 [61]. In 




) were genetically linked, the fusion peptides were deleted, 
and an additional disulfide bond was introduced, reducing the movement between 
the monomers. According to the authors, a major advantage of DS2 is its improved 
antigenic stability against heat inactivation (for 60 minutes at 60 °C). In addition, DS2 
adjuvanted with poly I:C induced an approximately four-fold higher VN activity than DS-
Cav1 in RSV-naïve CB6F1/J mice after two intramuscular immunizations. However, the 
(long-term) storage stability of DS2 was not investigated. The performed experiments 
only showed an increased antigenic stability upon heat shock. Moreover, no challenge 
study was performed. Therefore, further research is needed to demonstrate whether 
DS2 is suitable as an antigen.
In 2018, Zhang et al. [62] performed additional structure-based design on DS-
Cav1 to improve its stability, leading to a properly folded candidate named F111. To 
produce F111, the furin cleavage sites, the p27 peptide, and part of the fusion peptide 
were replaced with a twelve amino acid flexible linker. In addition, an inter-trimer 
disulfide mutation was introduced. Compared to DS-Cav1, F111 showed an improved 
heat stability and an improved prolonged storage stability at 4 °C (no increased 
4D7 (post-F-specific antibody) binding up to three months). However, it is not clear 
whether D25 binding (antigenic site Ø) remains stable over this period. A two-dose 
intramuscular immunization of BALB/c mice with F111 adjuvanted with aluminum 
showed no compromise in immunogenicity compared to DS-Cav1.
Krarup et al. [63] designed a highly stable pre-F vaccine candidate, named SC-DM, 
from structural analysis of the fusion mechanism. SC-DM is a single-chain (SC), with a 




 subunits, double mutant (DM) with an optimized apex. 
Using differential scanning fluorometry, SC-DM showed refolding from pre-F to post-F 
at 52 °C. In addition, heated SC-DM was unable to bind to CR9501, a pre-F-specific 
antibody. However, it was shown that SC-DM remained in its pre-F conformation for at 
least 50 days at 4 °C, in contrast to DS-Cav1. A two-dose intramuscular immunization of 
BALB/c mice with SC-DM (with or without poly I:C as adjuvant) resulted in significantly 
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higher neutralizing titers than a two-dose intramuscular immunization with post-F. 
Moreover, immunization with adjuvanted SC-DM resulted in 10-fold higher VN titers 
than immunization with adjuvanted post-F. Subsequently, a challenge study was 
performed in cotton rats with this vaccine candidate. Cotton rats were immunized 
intramuscularly twice with SC-DM (with or without AdjuPhos, an aluminum phosphate 
gel, as adjuvant) or twice with post-F (with or without AdjuPhos as adjuvant). The results 
were comparable to the results obtained in mice and showed a significant enhancing 
effect of AdjuPhos regarding VN titers elicited by SC-DM. Cotton rats immunized with 
5 µg adjuvanted SC-DM were completely protected from RSV challenge.  
The ‘head-only’ antigen designed by Boyington et al. [64] is based on the DS-
Cav1 antigen. These authors hypothesized that the head region of the F protein, i.e. 
the membrane-distal half with an intact antigenic site Ø (see Fig. 3), might elicit a 
better antibody response directed against the antigenic site Ø than the complete F 
protein. Therefore, the membrane-proximal half (stalk region) of the protein was 
removed and monomers, dimers, and trimers of the truncated protein were generated. 
Four of the ‘head-only’ antigens adjuvanted with poly I:C were studied in CB6F1/J 
mice. The ‘head-only’ antigen i-447, a trimeric antigen, showed the most promising 
results. Following two intramuscular administrations to mice, i-447 elicited VN titers 
comparable to those induced by DS-Cav1. However, higher levels of antibodies directed 
against antigenic site Ø were found than with DS-Cav1. Compared to DS-Cav1, i-447 
showed an increased thermostability (no loss of site Ø antigenicity when heated for 
60 minutes at 70 °C), although a heat shock for 60 minutes at 90 °C resulted in a 
substantial loss of site Ø antigenicity (only 10% remaining). Unfortunately, the stability 
of i-447 upon (prolonged) storage was not investigated. Moreover, a challenge study 
was not conducted.
Garg et al. [65] showed that a ∆F/TriAdj-vaccine protected rodents for at least 
one year from RSV infection. The ∆F/TriAdj-vaccine consists of a truncated shortened 
form of the native F protein (∆F). To produce ∆F, the transmembrane domain 
of the protein was deleted. The ∆F protein was formulated with three different 
adjuvants, namely poly I:C, an immune defense regulator peptide (IDR1002), and a 
polyphosphazene (poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP)). 
Intranasal immunization of BALB/c mice with this vaccine candidate induced higher 
mucosal IgA production than did two intranasally administered doses of live RSV A2 
strain. It also induced higher numbers of B-, Th-, and antibody-secreting plasma cells 
(in the lymph nodes), and elicited increased expression of interleukin (IL)-6, IL-21, and 
transforming growth factor-β, resulting in longer-lasting immunogenic protection 
than that induced by infection with live RSV [66]. In 2017, Garg et al. [67] showed 
that a single dose of intranasally administered ∆F/TriAdj-vaccine also resulted in a 
long-term protective immunity. BALB/c mice challenged 25 weeks post-immunization 
showed complete protection against RSV. In another study, ∆F/TriAdj was evaluated 
Subunit-based RSV vaccine candidates | Chapter 4
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as a maternal vaccine [68]. By vaccinating pregnant ewes twice, it was shown that the 
maternal antibodies (IgG) were transferred to the lambs. The lambs were challenged 
intranasally with RSV and had lower virus replication and lung pathology than control 
animals. This indicates that maternal immunization with ∆F/TriAdj might be safe and 
effective.
Passmore et al. [69] used an intranasally administered recombinant F protein 
(rF-ptn) adjuvanted with a nanoemulsion. Unfortunately, the conformation of the F 
protein was not described. The nanoemulsion consisted of Tween 80 (5%), ethanol 
(8%), cetyl pyridinium chloride (1%), soybean oil (64%), and water. This oil-in-water 
system with a droplet size of approximately 500 nm was mixed with rF-ptn to obtain 
the final formulation. The formulation was administered twice, intranasally, to BALB/c 
mice and gave good humoral (IgG and IgA) responses. High neutralization activity was 
found and an enhanced viral clearance after RSV challenge was seen. However, as mice 
were challenged two weeks after administration of the second dose of the vaccine, the 
duration of the immune response remained unclear.
Cherukuri et al. [70] investigated the effect of the adjuvant Al(OH)
3
 by 
intramuscularly vaccinating young (8 weeks) and aged (18 months) BALB/c mice twice 
with the F protein (conformation not described), with or without the Al(OH)
3
 adjuvant. 
After challenge, it appeared that the vaccine with Al(OH)
3
 protected both young and 
aged mice to a higher degree than the vaccine without adjuvant. Also, the vaccine with 
Al(OH)
3
 induced higher VN antibody titers in young mice (completely protected) than 
in aged mice. Therefore, a higher antigen dose and/or adjuvant might be needed for 
the elderly. The duration of the immune response was not investigated, as mice were 
challenged already two weeks after receiving the second dose of the vaccine.
In 2018, Khan et al. [71] produced FG-Gb1, a recombinant protein meant for 
intranasal vaccination. FG-Gb1 was produced by genetically fusing the core fragments 
of the F and the G proteins with Gb-1 (a microfold cell-specific ligand) by using a 
flexible linker. The authors hypothesized that by using Gb-1, the antigen is targeted 
to differentiated microfold cells of the nasopharynx-associated lymphoid tissue 
(NALT), leading to an efficient antigen delivery to the underlying immune induction 
site. To investigate this, BALB/c mice were intranasally immunized twice with either 
FG-Gb1 or FG (the fragments without Gb1). Mice that were immunized with FG-Gb1 
showed significant increases in antigen-specific serum IgG, IgG-secreting cells in the 
splenocytes, antigen-specific IgA-secreting cells, sIgA in NALT, and VN antibody titers 
compared to mice immunized with FG. In addition, mice immunized with FG-Gb1 were 
protected from RSV challenge. Unfortunately, the stability of the formulation and the 
duration of the immune response were not investigated.
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 Vaccine candidates in clinical development
 
In a phase I study, an RSV vaccine ultimately intended for pregnant women was tested 
with purified recombinant F protein in the pre-F conformation [72]. It was unclear 
how the antigen was stabilized in its pre-F conformation. The safety, reactogenicity, 
and immunogenicity were evaluated. In addition, the use of the adjuvant Al(OH)
3 
was 
investigated. In the trial, 128 healthy men, 18-44 years old (of whom 121 completed 
the study), received an intramuscular injection of the vaccine, containing 10, 30, or 
60 µg of pre-F protein, with or without 500 µg Al(OH)
3
. The vaccine elicited a rapid 
VN antibody (IgG) response (7 days after vaccination) and had an acceptable adverse 
events profile. The most commonly reported adverse events were temporary pain 
at the injection site and mild fatigue. The highest antibody titers were found in the 
groups that received 30 µg pre-F protein/Al(OH)
3
, 60 µg pre-F protein/Al(OH)
3
, or 60 µg 
pre-F protein without adjuvant. The antibody titers decreased at day 60 and decreased 
even further at day 180 and day 360. However, VN antibody titers for these three 
groups at day 360 were still higher than baseline. Unfortunately, no conclusions about 
the effects of the adjuvant Al(OH)
3 
could be drawn due to the relatively small sample 
size. In 2017, a planned phase II study aimed to evaluate the safety, reactogenicity, and 
immunogenicity of this vaccine in healthy pregnant women and postpartum in their 
infants was canceled due to instability of the pre-F antigen during manufacturing [73].
Another phase Ia study was conducted with a vaccine containing soluble fusion 
protein (sF) in adults over 60 years of age [74]. The post-F conformation of the F protein 
was used. Because the cell-mediated immune system of the target group (the elderly) 
is in general not easily stimulated, the addition of an adjuvant was applied to boost 
cellular and humoral immune responses. The synthetic analog of monophosphoryl 
lipid A, glucopyranosyl lipid A (GLA), was used as an adjuvant, which is a toll-like 
receptor 4 (TLR4) agonist. GLA was formulated in a 2% squalene-based oil-in-water 
emulsion (SE). In this study, subjects received the sF vaccine containing 20, 50, or 80 µg 
post-F protein with or without the adjuvant (2.5 µg of GLA in 2% SE) intramuscularly. 
The results of the study were promising, as the safety profile was acceptable for 
all doses studied and the adjuvant GLA-SE stimulated both humoral and cellular 
immune responses (micro-neutralization, RSV-specific IgG, and IFN-γ). The immune 
responses were dose-dependent and did not reach a plateau. Therefore, the efficacy 
of the vaccine was examined in a larger clinical Ib trial [75]. Subjects of ≥ 60 years 
received 120 µg sF with different doses of GLA-SE (1, 2.5, or 5 µg), or 80 µg sF with 2.5 
µg GLA-SE. The main objectives of the study were to investigate the tolerability and 
safety of the formulations, and to gather immunogenicity data for dose selection for 
a subsequent phase II study. The results of the phase Ib study showed that a higher 
GLA-SE dose augmented local tenderness and pain. However, even for the formulation 
with the highest dose of GLA-SE, the safety profile remained acceptable. The highest 
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immunogenic response was seen for the formulation containing 120 µg sF adjuvanted 
with 5 µg GLA-SE. Therefore, this formulation was selected for phase II evaluation. In 
2017, the results of this phase II study performed in 1,900 participants of ≥ 60 years 
showed that the vaccine was immunogenic, but did not protect from RSV illness [76]. 
A possible explanation for this outcome, given by the authors, was that the vaccine 
in the post-F conformation was not able to appropriately generate VN antibodies to 
prevent RSV illness due to the absence of antigenic site Ø.
In 2017, a phase I study was started with DS-Cav1, despite the fact that this RSV 
vaccine candidate underwent a conformational change upon long-term storage (102 




While, in the previous section, we discussed RSV subunit vaccine candidates based 
on soluble envelope glycoprotein antigens, this section reviews strategies to develop 
safe and efficient subunit vaccines based on the use of particulate formulations. 
Particulate vaccine formulations in general offer specific advantages over soluble 
protein vaccines, including multimeric antigen presentation and improved uptake and 
processing by antigen-presenting cells [78]. A further distinction within this category 





VLPs are supra-molecular complexes, resembling the structure of native viruses. VLPs 
are generally produced through expression of one or more viral structural proteins, such 
as surface glycoproteins derived from enveloped viruses, in prokaryotic or eukaryotic 
expression systems, and often contain a lipid envelope derived from the production cell 
system [79,80]. Several expression systems for generation of VLPs have been described, 
including E. coli, yeast, insect, or even plant cells [79,80]. A major advantage of VLPs is 
that they are known to induce potent B- and T-cell responses [81,82]. Using eukaryotic 
expression systems, VLPs containing RSV envelope glycoproteins have also been 
produced. This section is devoted to RSV vaccine candidates based on the use of VLPs 
containing the viral envelope glycoproteins, in particular the F protein. Table 2 gives an 
overview of the in vivo studies discussed in this review that used VLPs containing the 
viral envelope glycoproteins, in particular the F protein, as vaccine candidates.
Lee et al. [83] investigated whether immunization with a combination of VLPs 
containing the F protein and VLPs containing the G protein (VLP F + VLP G) leads to 
an enhanced vaccination efficacy compared to VLPs containing the F protein (VLP 
F) or VLPs containing the G protein (VLP G) alone. To investigate this, BALB/c mice 
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were vaccinated intramuscularly twice with either VLP F, VLP G, or VLP F + VLP G. All 
vaccine candidates were in complex with influenza M1, the conformation of the F 
protein was not investigated. It was shown that mice vaccinated with VLP F + VLP G 
had lower lung viral loads after RSV challenge, possibly due to an increased CD8 T-cell 
cytokine expression. However, VN antibody titers of mice vaccinated with VLP F alone 
were similar to mice vaccinated with VLP F + VLP G. Moreover, vaccination with VLP 
G resulted in an enhanced immunopathology. The duration of the immune response 
was not investigated, as the challenge experiment was performed three weeks after 
administration of the second dose of the vaccine.    
In a comparable study, Newcastle disease virus (NDV) was used as platform 
for VLPs containing the RSV F protein (rNDV/RSV/F) and/or G protein (rNDV/RSV/G) 
[84]. In this study, mice were intranasally vaccinated twice with either rNDV/RSV/F, 
rNDV/RSV/G, or a combination of both (rNDV/RSV/F+G). Mice that were vaccinated 
with rNDV/RSV/F+G showed the highest serum IgG titers, the highest nasal serum 
IgA titers, and highest levels of IFN-γ and IL-4. Moreover, mice vaccinated with rNDV/
RSV/F+G showed better protection after RSV challenge than mice vaccinated with 
rNDV/RSV/F or rNDV/RSV/G alone. Unfortunately, the conformation of the F protein 
was not described. In addition, it is not clear when the challenge experiments were 
performed. 
Cimica et al. [85] used the M protein of human metapneumovirus as scaffold 
together with recombinant post-F, pre-F, or a combination of both for their VLPs. The 
pre-F protein was stabilized by introducing two disulfide bonds. A squalene-based 
oil-in-water emulsion was used as adjuvant. Two intramuscular administrations with 
the vaccine containing both post-F and pre-F protein yielded complete protection 
against RSV challenge and no viral lung replication in challenged BALB/c mice was 
seen. Furthermore, this formulation showed a balanced Th1/Th2 response and gave 
the highest VN antibody titers, followed by the pre-F only formulation. The post-F 
protein VLP vaccine gave the lowest neutralizing antibody titers. Unfortunately, the 
(prolonged) stability of the formulation was not tested. Moreover, the duration of the 
immune response was not investigated, as the challenge experiment was performed 
already two weeks after administration of the second dose of the vaccine.
Cullen et al. [86] investigated whether previously RSV-infected mice generated 
protective immune responses when vaccinated with their VLPs. This study was 
performed to investigate the effect of pre-existing immunity on vaccination efficacy, 
which is important for vaccine candidates meant for pregnant women and the elderly. 
The authors used NDV core proteins to develop VLPs containing chimera H/G protein 
and either chimera pre-F/F (VLP-H/G+pre-F/F) or chimera post-F/F (VLP-H/G+post-
F/F), to investigate the influence of the conformation of the F protein on the immune 
response. Mice were first infected with RSV by intranasal inoculation. Then, 95 days 
post-infection, mice were immunized intramuscularly with either VLP-H/G+pre-F/F or 
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VLP-H/G+post-F/F. After vaccination, high VN antibody titers were observed in mice 
that were immunized with VLP-H/G+pre-F/F, in contrast to mice that were immunized 
with VLP-H/G+post-F/F. These results indicate that VLPs containing the F protein in its 
pre-F conformation are able to induce a VN antibody memory response, in contrast to 
VLPs containing the post-F conformation. Therefore, the conformation of the F protein 
seems to be of great importance in vaccine candidates intended for pregnant women 
and the elderly.
In 2018, the efficacy of VLP-H/G+pre-F/F and VLP-H/G+post-F/F was assessed in 
a maternal immunization model using cotton rats [87]. A subgroup of female cotton 
rats was intranasally infected with RSV. Subsequently, all female cotton rats were set 
up in breeding pairs at week 8. At week 10, pregnant cotton rats were intramuscularly 
vaccinated with VLP-H/G+pre-F/F, VLP-H/G+post-F/F, purified pre-F, or purified post-F. 
At 12 weeks, cotton rats delivered their pups, which were intranasally challenged with 
RSV at 4 weeks of age. The results of this study were comparable to the results of the 
previous study and showed that VLPs containing pre-F were more efficient in boosting 
pre-existing VN antibodies than VLPs containing post-F. In addition, VLPs containing 
pre-F were also more efficient than purified F protein (pre-F as well as post-F). Pups 
born to mothers that were immunized with VLP-H/G+pre-F/F showed enhanced 
VN antibody titers and protection of the lung from RSV replication after challenge. 
Unfortunately, the (prolonged) stability of the formulation was not tested.
Nanoparticles
 
In recent years, the use of nanotechnology in vaccine development increased 
significantly. Nanoparticles are more simple structures than VLPs, usually lacking a 
lipid envelope and consisting of a self-assembled oligomeric viral protein, such as - for 
example - RSV F. The main advantages of nanoparticle-based vaccines are an increased 
antigen stability and an enhanced immunogenicity [88,89]. Table 3 gives an overview 
of the in vivo studies discussed in this review that used nanoparticles containing the 
viral envelope glycoproteins, in particular the F protein, as vaccine candidates.
A recombinant F protein nanoparticle vaccine was developed by Smith et al. [90]. 
This vaccine contained a modified almost full length F protein produced in Spodoptera 
frugiperda insect cells infected with a recombinant baculovirus. The nanoparticles 
(approximately 40 nm in size) were composed of F protein oligomers arranged in the 
form of rosettes without a lipid envelope. The F protein oligomers had a morphology 
consistent with the post-F conformation. Different doses (1, 6, or 30 µg) with or 
without 120 µg AlPO
4
 as adjuvant were tested. All doses protected cotton rats from 
RSV challenge after a two-dose intramuscular immunization. High serum IgG levels 
and neutralizing activity were found for the animals vaccinated with the F protein 
nanoparticles, the highest titers were found with the adjuvanted vaccine candidate. 
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Immunization of cotton rats with the vaccine containing AlPO
4 
elicited serum levels 
of palivizumab-competing antibodies greater than after passive administration of 
palivizumab [91]. Therefore, the vaccine is potentially more broadly protective than 
palivizumab. Unfortunately, no (prolonged) stability data were available and the 
duration of the immune response is not clear, as the animals were challenged 4 weeks 
after receiving the second dose of the vaccine.
Recombinant F protein nanoparticle vaccines based on the vaccine developed 
by Smith et al. [90] described above, are under clinical evaluation. The vaccines are 
meant for pregnant women in their third trimester, the elderly, and children with an 
age between 6 months and 5 years. In a phase III study with 11,850 participants (≥ 60 
years), the nanoparticle vaccine meant for the elderly failed to show efficacy against 
RSV moderate-severe lower respiratory tract disease [92–94].
As a phase III study for the vaccine meant for pregnant women is still ongoing, 
this vaccine will be discussed in more detail. The nanoparticle vaccine for pregnant 
women was first tested in pregnant guinea pigs [95] and two clinical trials in healthy 
women of childbearing age were subsequently performed. The pregnant guinea 
pigs were immunized twice with 30 µg F protein with or without 400 µg AlPO
4
. Both 
the non-adjuvanted and adjuvanted vaccine yielded high IgG titers, palivizumab-
competing antibodies, and serum showed RSV neutralizing activity in vitro. However, 
the adjuvanted vaccine gave a more potent immune response. The results showed 
adequate antibody transfer to the pups for both the adjuvanted and the non-
adjuvanted groups. In the first phase II clinical study, healthy non-pregnant women 
(18-35 years old) were intramuscularly immunized with 1 or 2 dose(s) of the vaccine 
(60 or 90 µg) with or without 1.2 mg AlPO
4
 as adjuvant [96]. The vaccine appeared to be 
safe, immunogenic, and reduced RSV infections. High serum IgG antibody levels were 
found in all groups, which were still detectable after 112 days. The best results were 
obtained when the vaccine with adjuvant was administered twice. A modest increase 
in antibody levels was observed for the higher antigen dose (90 µg). For the second 
phase II study, non-pregnant women (18-35 years old) were vaccinated intramuscularly 
with 1 or 2 dose(s) of 60 µg or 120 µg adjuvanted with 0.2, 0.4, or 0.8 mg AlPO
4 
[97]. 
All formulations were immunogenic and well tolerated. The formulation of a single 
dose of 120 µg adjuvanted with 0.4 mg AlPO
4 
was the formulation with an optimal 
combination in terms of efficacy and convenience. The safety and immunogenicity of 
the F protein nanoparticle vaccine, with AlPO
4
, is currently being studied in healthy, 
pregnant women in their third trimester. In this phase III study, 4,636 third trimester 
pregnant women were enrolled [98,99]. The study completion date is estimated by 
July 2019. However, it was recently reported that the study did not meet its primary 
objective (prevention of medically significant RSV lower respiratory tract infections) 
[99]. The efficacy of the vaccine through 90 days of life in infants against medically 
significant RSV lower respiratory tract infections was reported to be 39.4% [100].
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In 2018, Gilbert et al. [101] characterized the immune response to the RSV F 
nanoparticle vaccine described above. To this end, the authors immunized cotton rats 
intramuscularly twice with 10 µg of the RSV F nanoparticle vaccine with or without 
60 µg aluminum phosphate as adjuvant. Subsequently, sera were analysed on cross-
competition of F antigenic site specific monoclonal antibodies, namely: D25 for site 
Ø (pre-F-specific), motavizumab for site II, NVX for site IV, and hRSV90 for site VIII 
(pre-F-specific). Despite the fact that a morphology consistent with that of the post-F 
conformation was previously reported for this candidate [90], the serum of cotton rats 
that had been immunized with the RSV F nanoparticle vaccine cross-competed with 
all monoclonal antibodies, including the pre-F-specific monoclonal antibodies D25 and 
hRSV90. This was also supported by the fact that cotton rats immunized with the RSV 
F nanoparticle vaccine were protected against challenge with a palivizumab-resistant 
mutant virus. These data show that multiple neutralizing epitopes, including the pre-
F-specific sites Ø and VIII, are targeted upon immunization with the RSV F nanoparticle 
vaccine. Cotton rats immunized with the adjuvanted vaccine showed higher anti-F 
IgG and micro-neutralizing titers. In addition, the adjuvant increased site II antibody 
avidity, which resulted in an enhanced protection against RSV challenge.
Francica et al. [102] used TLR agonists as adjuvants to an F protein (in the pre-F 
conformation (DS-Cav1)) vaccine to enhance antibody responses in CB6F1/J mice. The 
authors discovered that conjugation of F protein to TLR7/8a disrupts the recognition 
of critical VN epitopes. However, if the F protein was coupled to nanoparticle-
forming thermoresponsive diblock copolymers (consisting of N-(2-hydroxypropyl) 
methacrylamide (HPMA) and di(ethylene glycol) methyl ether methacrylate (DEGMA)) 
and if TLR7/8a was used as adjuvant, high titers of pre-F-specific antibodies mediated 
by Th1 cells were obtained. This formulation seems to have appropriate antigenicity, 
as the mice were fully protected from RSV challenge after being immunized 
subcutaneously twice. However, the duration of the immune response is unclear, since 
the mice were challenged only 17 days after vaccination. Moreover, the (long-term) 
storage stability of the formulation was not investigated.
 
Virosomes
Virosomes are VLPs, in the sense that they closely resemble the virus they are derived 
from. However, unlike the VLPs discussed above, virosomes are produced from native 
virus through a detergent solubilization and subsequent reconstitution procedure. 
Thus, virosomes are reconstituted viral envelopes. They lack the viral genetic material 
and therefore are non-replicating. Virosomes have been originally produced from 





), Stegmann et al. [104] demonstrated that the envelope of influenza virions 
could be efficiently solubilized; after sedimentation of the viral nucleocapsid through 
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 from the supernatant by 
the addition of a hydrophobic resin, reconstituted viral envelopes were formed which 
retained the viral receptor-binding and membrane fusion activities. In a follow-up 




 was replaced by a short-




, DCPC is 
removable by dialysis because of its high critical micelle concentration.
Since virosomes retain the morphology and cell interaction characteristics of the 
native virus, they represent excellent non-replicating vaccine formulations. This has 
been demonstrated extensively for virosomes derived from influenza virus [106]. Not 
only can influenza virosomes be used as vaccine against influenza infection, they may 
also be employed as carriers of foreign antigens, for induction of both antibody and 
cell-mediated immune responses, including CD8 T-cell responses [106]. An additional 
advantage of virosomes relates to the opportunity to incorporate lipophilic or 
amphiphilic adjuvants in the virosome membrane during the reconstitution procedure 
[106]. Table 4 shows an overview of the in vivo studies discussed in this review that 
used RSV virosomes as vaccine candidates. 
Table	 4. An overview of the in vivo studies discussed in this review that used RSV virosomes as vaccine 
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IM: Intramuscular; IN: Intranasal; L18-MDP: 6-O-stearoyl-N-Acetyl-muramyl-L-anayl-D-isoglutamine; MPLA: 
Monophosphoryl lipid A; P3CSK4: N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-
[S]-(lysyl)
3
-lysine. ± indicates with or without adjuvant.
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Using the DCPC-dialysis procedure, virosomes have been produced from RSV 
and evaluated for their immunogenicity in animal model systems. Initial studies were 
carried out by Stegmann et al. [107] and Kamphuis et al. [108–110], who incorporated 
TLR2- or TLR4-ligands as vaccine adjuvants in the virosomal membrane, respectively. 
When administered intramuscularly to mice or cotton rats, these virosomes induced 
robust VN antibody and T helper cell responses, with a balanced Th1/Th2 signature. Also, 
they provided complete protection from viral infection upon challenge [107,108,110]. 
In addition, in mice [109,111] and cotton rats [109], protective immunity may also be 
induced by intranasal administration of adjuvanted virosomal RSV vaccines.  
More recently, the incorporation of TLR4-ligands, in particular non-toxic variants 
of bacterial monophosphoryl lipid A (MPLA), as adjuvants in virosomal RSV candidates 
has further been investigated [112]. An important improvement to the use of this 
potent adjuvant system relates to the use of the fully synthetic MPLA-derivative 
3D-PHAD®, produced by Avanti Polar Lipids, allowing vaccine production under GMP 
conditions. The authors of the latter study also investigated the morphology and 
long-term stability of the 3D-PHAD-containing RSV virosomes. Single particle tracking 
showed that the virosomes were stable for 300 days at 4 °C.
CONCLUSION
 
For a long time, there has been a reluctance toward the development of an RSV vaccine 
due to the failure and dramatic outcome of a study published in 1969, in which two 
young children, vaccinated with an experimental FI-RSV vaccine, died due to vaccine-
enhanced respiratory disease after exposure to a natural RSV infection [17]. Since this 
disastrous FI-RSV vaccine trial, vaccination of very young children against RSV has 
remained elusive. However, there is now a growing interest in vaccination of pregnant 
women to passively protect infants against RSV in the crucial first months of their life. 
Subunit-based vaccines are explicitly considered for this purpose. In addition, this type 
of vaccine is also considered for vaccinating another important target population, the 
elderly. This is the reason why over the last years, research has been intensified toward 
development of safe and effective subunit-based RSV vaccines. This review focused 
on subunit-based RSV vaccines using the viral envelope glycoproteins, in particular 
the F protein, as antigens. The F protein has proven to be an effective antigen in both 
the pre-F and post-F conformation, and subunit-based vaccine candidates using the 
F protein as antigen have been shown to elicit high titers of VN antibodies. However, 
as yet, no vaccine candidate has been able to elicit robust protective immunity, as 
demonstrated by multiple failed clinical trials. Three of the recently failed clinical 
studies used vaccine candidates with post-F protein or with a morphology consistent 
with that of the post-F conformation [76,92–94,98–100], suggesting the importance 
of the pre-F-specific antigenic sites and the pre-F morphology in eliciting protective 
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immunity. Although a morphology consistent with that of the post-F conformation was 
reported for the nanoparticle-based vaccine candidate [90], it has been shown that the 
vaccine candidate induced antibodies that competed with pre-F-specific monoclonal 
antibodies [101], suggesting unknown factors in RSV subunit vaccine development. 
The of use of pre-F as antigen presents stability challenges, as demonstrated by a 
recently canceled phase II study with a vaccine candidate in the pre-F conformation 
[73]. Therefore, induction of protective immunity and preservation of vaccine stability 
remain challenges in the development of subunit-based RSV vaccines using the viral 




Although many of the vaccine candidates described in this review showed promising 
results in animal models and some even in human trials, apparent weaknesses are 
obvious and should be addressed as well. Most studies showed that immunization 
with the vaccine candidate resulted in high titers of neutralizing antibodies. However, 
in vivo challenge experiments were not always carried out. The ultimate goal of 
vaccination is to elicit (long-lasting) protective immunity. While some animal studies 
did include in vivo challenge experiments, these were usually carried out already 2-5 
weeks after the (booster) immunization. This is rather a short period of time, since it 
is well known that humoral immunity against RSV decreases over time [72,113]. By 
contrast, there are some studies that have investigated the induction of long-term 
memory in animals [65–67]. These studies showed that it was possible to induce 
long-term memory with a subunit RSV vaccine based on the F protein. However, that 
eliciting a protective immune response is far from trivial is also indicated by the failure 
of a phase II [76] and two phase III [92–94,98–100] studies. For these trials, the post-F 
protein or a nanoparticle-based vaccine candidate with a morphology consistent with 
that of the post-F conformation was used, respectively. The post-F conformation, as 
previously discussed, lacks important pre-F-specific antigenic sites, such as antigenic 
sites Ø and VIII [47,49,50]. The absence of these important epitopes may be the reason 
why the phase II trial failed. However, with the nanoparticle-based vaccine candidate, 
which had a morphology consistent with that of post-F [90], antibodies competing 
with pre-F-specific monoclonal antibodies were induced [101]. These results suggest 
unknown factors in RSV subunit vaccine development.
A vaccine candidate based on pre-F might be more immunogenic. However, 
using pre-F as antigen presents its own challenges. In 2017, a phase II study with a 
vaccine containing pre-F was canceled due to instability of the pre-F antigen during 
manufacturing [73]. This illustrates the major concern regarding the use of pre-F as 
antigen. Modified vaccines based on the pre-F antigen were developed. However, 
except for two formulations (DS-Cav1 and SC-DM), no data are available on the 
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storage stability of these vaccine candidates. It should furthermore be noticed that 
all formulations described in this review are liquid (aqueous) formulations, with 
concomitant disadvantages, such as a poor (storage) stability. To prevent deterioration, 
liquid formulations require strictly monitored refrigeration during storage and 
transport, known as the cold-chain, which implicates logistic challenges. To overcome 
the disadvantages related to liquid formulations, the development of a dry powder 
vaccine may be an elegant solution [114–116]. However, an important consideration 
to take into account is that the drying process itself may be detrimental to the antigen, 
i.e. it may result in conformational changes and/or loss of activity [114]. Excipients can 
be used to prevent this. Certain sugars (e.g. trehalose, sucrose, or inulin) are known to 
stabilize proteins during drying and subsequent storage and are therefore interesting 
excipients to be used for the development of such dry powder vaccines [116,117]. 
Although to our knowledge, pre-F has never been stabilized by drying, several 
other subunit vaccines have been processed into a stable dry powder, e.g. influenza 
haemagglutinin [118] and hepatitis B surface antigen [119].
A dry powder RSV vaccine based on pre-F would not only show improved 
(storage) stability, it might also increase the efficacy of intranasal administration of 
the vaccine. A disadvantage of liquid intranasal vaccine formulations is their generally 
poor absorption over the nasal mucosa, limiting their efficacy. This problem can be 
overcome by incorporating mucoadhesive excipients, such as chitosan, in a dry powder 
vaccine formulation [120]. This will improve the absorption of the vaccine over the 
nasal mucosa and therefore increase the efficacy of the vaccine formulation, but 
may also have adverse effects, including ciliotoxicity, that should be considered when 
alternative formulations are developed.  
A major advantage of a dry powder RSV vaccine based on pre-F would be the 
possibility of pulmonary administration. This route of administration is interesting 
because pulmonary vaccination against other airborne diseases (influenza and 
measles) has been proven successful in humans in several studies [121–126]. 
Furthermore, the lung is the site where RSV-related pneumonia takes place [127]. The 
pulmonary administration route for vaccines has the potential to elicit both a systemic 
(IgG) and mucosal (IgA) immune response [114,115]. It is known that RSV-specific 
IgA has a protective role against RSV infection [128]. This could lead to an enhanced 
(longer-lasting and stronger) immune response [115]. Indeed, Amorij et al. [129], using 
an influenza subunit vaccine, have demonstrated that the pulmonary administration 
route has the capacity to elicit robust systemic humoral (IgG), mucosal humoral (IgG 
and IgA), and cell-mediated immune responses in BALB/c mice. Pulmonary administered 
dry powder measles vaccine formulations have also been successfully used in cotton 
rats [130] and rhesus macaques [131]. A pulmonary administered dry powder vaccine 
has several advantages over a pulmonary administered liquid vaccine, as described 
by Tonnis et al. [132]. However, for such a pulmonary vaccine to be successful, a 
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combination between a suitable delivery device and an optimal vaccine formulation 
is required [132]. For pregnant women and for the elderly, a dry powder vaccine could 
be administered by using a disposable (single-dose) inhaler, such as the Twincer®. 
The ability of this inhaler to accurately deliver drugs and its ease in use have been 
documented [133]. In conclusion, the development of a dry powder subunit-based 
RSV vaccine formulation using pre-F for pulmonary administration may overcome the 
disadvantages presented by most vaccine candidates discussed in this review.
In the near future, the development of subunit-based RSV vaccines using the 
viral envelope glycoproteins, in particular the F protein, as antigens will remain an 
interesting approach in the development of effective RSV vaccines. The failure of 
three recent clinical trials will shift research into the direction of antigens in the pre-F 
conformation and with a morphology consistent with that of pre-F, since this form has 
important pre-F-specific antigenic sites, including antigenic sites Ø and VIII. In view 
of the poor stability of this conformation, innovative stabilization technologies are 
needed and they will be essential in developing vaccine concepts that are suitable for 
widespread use. Finally, research toward the development of dry powder subunit-based 
RSV vaccines, based on stabilized pre-F, will be worthwhile. Pulmonary administration 
of such dry powder RSV vaccines should be explored as it may yield clinically relevant 
results.
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